Ubs Asset Management Americas Inc Abb Vie Inc. Transaction History

Ubs Asset Management Americas Inc

$277 Billion
Q1 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 8,754,961 shares of ABBV stock, worth $1.5 Billion. This represents 0.58% of its overall portfolio holdings.

Number of Shares

8,754,961

Previous 8,843,986 1.01%

Holding current value

$1.5 Billion

Previous $1.37 Billion 16.32%

% of portfolio

0.58%

Previous 0.55%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $14.2 Million - $16.2 Million	-89,025 Reduced 1.01%	8,754,961 $1.59 Billion
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $77.4 Million - $87.1 Million	-562,261 Reduced 5.98%	8,843,986 $1.37 Billion
Q3 2023 Nov 13, 2023	SELL	$133.59 - $154.65 $77.1 Million - $89.3 Million	-577,122 Reduced 5.78%	9,406,247 $1.4 Billion
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $114 Million - $131 Million	-786,314 Reduced 7.3%	9,983,369 $1.59 Billion
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $8.44 Million - $10.1 Million	-60,995 Reduced 0.56%	10,769,683 $1.74 Billion

Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $24.3 Million - $27.8 Million	-180,708 Reduced 1.64%	10,830,678 $1.45 Billion
Q2 2022 Aug 12, 2022	BUY	$137.62 - $174.96 $129 Million - $164 Million	938,091 Added 9.31%	11,011,386 $1.69 Billion
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $140 Million - $174 Million	-1,064,271 Reduced 9.56%	10,073,295 $1.63 Billion
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $118 Million - $149 Million	-1,096,380 Reduced 8.96%	11,137,566 $1.51 Billion
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $124 Million - $141 Million	1,166,720 Added 10.54%	12,233,946 $1.32 Billion
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $45.1 Million - $50.3 Million	-429,138 Reduced 3.73%	11,067,226 $1.25 Billion
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $5.92 Million - $6.51 Million	57,833 Added 0.51%	11,496,364 $1.24 Billion
Q4 2020 Mar 01, 2021	BUY	$80.49 - $108.67 $182 Million - $246 Million	2,263,374 Added 24.67%	11,438,531 $1.23 Billion
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $36.6 Million - $43 Million	426,045 Added 4.87%	9,175,157 $804 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $196 Million - $262 Million	2,666,133 Added 43.83%	8,749,112 $859 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $18.7 Million - $28.4 Million	290,574 Added 5.02%	6,082,979 $463 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $5.25 Million - $6.57 Million	-72,771 Reduced 1.24%	5,792,405 $513 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $8.92 Million - $10.7 Million	141,629 Added 2.47%	5,865,176 $444 Million
Q2 2019 Aug 15, 2019	SELL	$65.7 - $83.98 $269,567 - $344,569	-4,103 Reduced 0.07%	5,723,547 $0
Q1 2019 May 14, 2019	BUY	$77.14 - $90.79 $12.9 Million - $15.2 Million	167,401 Added 3.01%	5,727,650 $0
Q4 2018 Feb 13, 2019	SELL	$77.85 - $96.01 $2.74 Million - $3.38 Million	-35,240 Reduced 0.63%	5,560,249 $513 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $3.87 Million - $4.31 Million	-43,583 Reduced 0.77%	5,595,489 $0
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $24.9 Million - $29.4 Million	-277,013 Reduced 4.68%	5,639,072 $0
Q1 2018 May 14, 2018	BUY	$92.01 - $123.21 $18.4 Million - $24.7 Million	200,298 Added 3.5%	5,916,085 $0
Q4 2017 Feb 09, 2018	SELL	$89.56 - $98.21 $19 Million - $20.8 Million	-211,917 Reduced 3.58%	5,715,787 $0
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $414 Million - $529 Million	5,927,704	5,927,704 $0

Others Institutions Holding ABBV

# of Institutions

3,651

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $303B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Abb Vie Inc. Transaction History